Literature DB >> 29800049

Overall and Subgroup Prevalence of Crohn Disease Among Patients With Hidradenitis Suppurativa: A Population-Based Analysis in the United States.

Amit Garg1, Jessica Hundal1, Andrew Strunk1.   

Abstract

Importance: Limited evidence supports a link between hidradenitis suppurativa (HS) and Crohn disease (CD), and this relationship has not been established in the United States. Objective: To evaluate the prevalence of CD among patients with HS in the United States and to determine the strength of association between the 2 conditions. Design, Setting, and Participants: Cross-sectional analysis of data from 51 340 patients with HS identified using electronic health records data in the Explorys multiple health system data analytics and research platform, which includes data from more than 50 million unique patients across all US census regions. Main Outcomes and Measures: Primary outcome was diagnosis of CD.
Results: Of the 18 455 660 total population considered, 51 340 had HS (35 000 women). Of these patients with HS, 29 010 (56.5%) were aged 18 to 44 years; 17 580 (34,2%), 45 to 64 years; and 4750 (9.3%), 65 years or older. Prevalence of CD among patients with HS was 2.0% (1025/51 340), compared with 0.6% (113 360/18 404 260) among those without HS (P < .001). Prevalence of CD was greatest among patients with HS who were white (2.3%), aged 45 to 64 years (2.4%), nonobese (2.8%), and tobacco smokers (2.3%). In univariable and multivariable analyses, patients with HS had 3.29 (95% CI, 3.09-3.50) and 3.05 (95% CI, 2.87-3.25) times the odds of having CD, respectively, compared with patients without HS. Crohn disease was associated with HS across all patient subgroups. The association was strongest for men (OR, 3.61; 95% CI, 3.24-4.03), patients aged 45 to 64 years (OR, 3.49; 95% CI, 3.16-3.85), nonobese patients (OR, 4.09; 95% CI, 3.69-4.54), and nonsmokers (OR, 3.44; 95% CI, 3.10-3.82). Conclusions and Relevance: These data suggest that patients with HS are at risk for CD. Gastrointestinal symptoms or signs suggestive of CD warrant additional evaluation by a gastroenterologist.

Entities:  

Mesh:

Year:  2018        PMID: 29800049      PMCID: PMC6128495          DOI: 10.1001/jamadermatol.2018.0878

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  47 in total

1.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

Review 2.  Inflammatory bowel disease: clinical aspects and established and evolving therapies.

Authors:  Daniel C Baumgart; William J Sandborn
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

Review 3.  Pathogenesis and pharmacotherapy of Hidradenitis suppurativa.

Authors:  Maiwand Nazary; H H van der Zee; E P Prens; Gert Folkerts; Jurr Boer
Journal:  Eur J Pharmacol       Date:  2011-09-14       Impact factor: 4.432

4.  The truth about cigarette smoking and the risk of inflammatory bowel disease.

Authors:  Greg Rosenfeld; Brian Bressler
Journal:  Am J Gastroenterol       Date:  2012-09       Impact factor: 10.864

5.  Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study).

Authors:  Simon S M Chan; Robert Luben; Anja Olsen; Anne Tjonneland; Rudolf Kaaks; Birgit Teucher; Stefan Lindgren; Olof Grip; Timothy Key; Francesca L Crowe; Manuela M Bergmann; Heiner Boeing; Göran Hallmans; Pontus Karling; Kim Overvad; Domenico Palli; Giovanna Masala; Hugh Kennedy; Fiona vanSchaik; Bas Bueno-de-Mesquita; Bas Oldenburg; Kay-Tee Khaw; Elio Riboli; Andrew R Hart
Journal:  Am J Gastroenterol       Date:  2013-01-15       Impact factor: 10.864

6.  Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?

Authors:  Lukasz Matusiak; Andrzej Bieniek; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2009-11       Impact factor: 4.437

7.  Epidemiology and natural history of inflammatory bowel diseases.

Authors:  Jacques Cosnes; Corinne Gower-Rousseau; Philippe Seksik; Antoine Cortot
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

8.  An exploration of the complex relationship of socioecologic factors in the treatment and outcomes of acute myocardial infarction in disadvantaged populations.

Authors:  J J Shen; T T Wan; J B Perlin
Journal:  Health Serv Res       Date:  2001-08       Impact factor: 3.402

9.  The prevalence of Crohn's disease in Israel: a 20-year survey.

Authors:  Ibrahim Zvidi; Rachel Hazazi; Shlomo Birkenfeld; Yaron Niv
Journal:  Dig Dis Sci       Date:  2008-07-24       Impact factor: 3.199

10.  Neighborhood socioeconomic status, Medicaid coverage and medical management of myocardial infarction: atherosclerosis risk in communities (ARIC) community surveillance.

Authors:  Randi E Foraker; Kathryn M Rose; Eric A Whitsel; Chirayath M Suchindran; Joy L Wood; Wayne D Rosamond
Journal:  BMC Public Health       Date:  2010-10-21       Impact factor: 3.295

View more
  9 in total

1.  Comparative Overall Comorbidity Burden Among Patients With Hidradenitis Suppurativa.

Authors:  Sarah Reddy; Andrew Strunk; Amit Garg
Journal:  JAMA Dermatol       Date:  2019-07-01       Impact factor: 10.282

2.  Opportunistic Infections Are More Prevalent in Crohn's Disease and Ulcerative Colitis: A Large Population-Based Study.

Authors:  Mohammed Zaahid Sheriff; Emad Mansoor; Jay Luther; Ashwin N Ananthakrishnan; Mohannad Abou Saleh; Edith Ho; Farren B S Briggs; Maneesh Dave
Journal:  Inflamm Bowel Dis       Date:  2020-01-06       Impact factor: 5.325

3.  Quantifying Risk Factors for Atrial Fibrillation: Retrospective Review of a Large Electronic Patient Database.

Authors:  Jaclyn Rivington; Patrick Twohig
Journal:  J Atr Fibrillation       Date:  2020-10-31

Review 4.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

5.  Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice.

Authors:  Errol P Prens; Aida M Lugo-Somolinos; Amy S Paller; Francisco Kerdel; Yinghui Duan; Henrique D Teixeira; Michelle Longcore; Alexa B Kimball
Journal:  Am J Clin Dermatol       Date:  2020-08       Impact factor: 7.403

6.  The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study.

Authors:  Yi-Teng Hung; Puo-Hsien Le; Chia-Jung Kuo; Yu-Chuan Tang; Meng-Jiun Chiou; Cheng-Tang Chiu; Chang-Fu Kuo; Yu-Huei Huang
Journal:  J Clin Med       Date:  2021-03-22       Impact factor: 4.241

Review 7.  Skin manifestations in spondyloarthritis.

Authors:  Katharina Meier; Alexandra Schloegl; Denis Poddubnyy; Kamran Ghoreschi
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-08       Impact factor: 5.346

Review 8.  Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.

Authors:  Amit Garg; Neeta Malviya; Andrew Strunk; Shari Wright; Afsaneh Alavi; Raed Alhusayen; Ali Alikhan; Steven D Daveluy; Isabelle Delorme; Noah Goldfarb; Wayne Gulliver; Iltefat Hamzavi; Tarannum Jaleel; Alexa B Kimball; Joslyn S Kirby; Mark G Kirchhof; Janice Lester; Hadar Lev-Tov; Michelle A Lowes; Robert Micheletti; Lauren A Orenstein; Vincent Piguet; Christopher Sayed; Jerry Tan; Haley B Naik
Journal:  J Am Acad Dermatol       Date:  2021-01-23       Impact factor: 15.487

9.  New insights in hidradenitis suppurativa from a population-based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities.

Authors:  Lisette M Prens; Klasiena Bouwman; Lisa D Troelstra; Errol P Prens; Behrooz Z Alizadeh; Barbara Horváth
Journal:  Br J Dermatol       Date:  2022-05       Impact factor: 11.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.